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Clinical and neuropathological similarities between dementia with Lewy bodies (DLB), Parkinson’s and
Alzheimer’s diseases (PD and AD, respectively) suggest that these disorders may share etiology. To test this
hypothesis, we have performed an association study of 54 genomic regions, previously implicated in PD or AD,
in a large cohort ofDLB cases and controls. The cohort comprised 788DLBcases and 2624 controls. Tominimize
the issue of potential misdiagnosis, we have also performed the analysis including only neuropathologically
provenDLB cases (667 cases). The results show that theAPOE is a strong genetic risk factor for DLB, confirming
previous findings, and that the SNCA and SCARB2 loci are also associated after a study-wise Bonferroni correc-
tion, although thesehaveadifferent associationprofile than the associations reported for the same loci inPD.We
havepreviouslyshownthat thep.N370Svariant inGBA isassociatedwithDLB,which, togetherwith thefindingsat
theSCARB2 locus,suggestsarole for lysosomaldysfunction in thisdisease.Theseresults indicate thatDLBhasa
unique genetic risk profile when compared with the twomost common neurodegenerative diseases and that the
lysosomemay play an important role in the etiology of this disorder. Wemake all these data available.
INTRODUCTION
Dementia with Lewy bodies (DLB) is commonly regarded as the
second largest neuropathological subgroup of neurodegenerative
dementing disorders, precededonlyby Alzheimer’sdisease (AD)
(1). DLB and Parkinson’s disease with dementia (PDD) are both
progressive neurodegenerative disorders and together they
account for 15–20% of all people with dementia (2). The clinical
characteristics of DLB include cognitive decline, parkinsonian
signs, fluctuations in cognition and attention, and visual halluci-
nations (3). Neuropathological diagnosis of DLB is based on the
widespread finding of Lewy bodies (LB) throughout the nervous
system, both CNS and PNS. The overlap in clinical presentation
between DLB and both AD and PDD, often causes difficulty in
diagnosing DLB (4). The incidence of motor symptoms in
patients with AD is much higher than expected in age-matched
controls (5). Dementia is frequent in late phases of PD and
present in up to 80% of patients with 20-year duration of motor
symptoms (6). If dementia occurs before or within the first year
from the start of the motor symptoms, the patients are diagnosed
with DLB (7). Neuropathological examination is not always con-
clusive for a diagnosis of DLB. A proportion of DLB neuropatho-
logically diagnosed patients present concomitant AD pathology
in various degrees (8), and LBs are the hallmark of PD with
and without dementia, thus increasing the problems with diagno-
sis. On the other hand, the fact that these three disorders have
overlaps in both clinical presentations and in neuropathological
features suggests that they may also share etiology.
Over the last few years, several advances in the understanding
of the genetics underlying neurological diseases have been made.
Several loci, and sometimes genes,havebeen conclusively shown
to modulate risk for a given phenotype. This was the case for both
AD (9–12) and PD (13,14) each with several publications repli-
cating initial findings. The same however has not been true for
DLB and the disease etiology still remains mostly elusive, with
only a small number of reports suggesting the involvement of
APOE and GBA as risk factors for the development of the
disease (15–18). DLB is generally considered a sporadic dis-
order,buta few casesof familial aggregation have beendescribed.
However, even in such cases, the identification of the underlying
causal gene has not been a successful endeavor (19).
Given the similarities between DLB and both PD and AD, at
the clinical as well as at the neuropathological level, we have
tested the most recently associated loci for AD and PD, in a
large multi-national cohort of DLB cases and controls.
RESULTS
The final analysis data set comprised of 788 cases and 2624 con-
trols, with genotypes at 6078 loci. These loci were selected from
the NeuroX array, based on 500 kb flanking regions of each top as-
sociation hit from the latest PD and AD genome-wide association
studies (GWAS). Supplementary Material, Table S1 details these
regions, as well as the level of coverage in NeuroX for each of the
reported top hits. The majority of top hits are well covered in our
study with markers showing r-squared values .0.6.
Three regions showed evidence of strong association with
DLB: the APOE, SNCA and the SCARB2 loci (Table 1). The
first is a widely known genetic risk factor for AD and has also
Table 1. Most significantly associated hits from the present study and comparison with previously reported hits from PD and AD associations
Study/named region Reported top hit Reported P-value Reported OR Best DLB hit P-value OR (95% CI)
AD_IGAP2013:APOE NA NA NA exm-rs769449 1.52E240 2.786 (2.397–3.239)
PD_MegaMeta:SNCA rs356182 4.16x-73 0.76 NeuroX_rs894280 1.67E206 0.754 (0.6725–0.8468)
PD_MegaMeta:FAM47E/SCARB2 rs6812193 2.95x-11 0.907 NeuroX_rs6825004 1.35E205 0.749 (0.658–0.854)
6140 Human Molecular Genetics, 2014, Vol. 23, No. 23
 at U
CL Library Services on M
ay 5, 2015
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
been reported to be a risk factor for DLB in smaller size studies,
the other two loci are known to impart risk for PD, albeit with
very disparate effect sizes. Figure 1 shows a genomic overview
of the association and Supplementary Material, Table S2 com-
pares the most significant results from this study with the previ-
ously reported hits at each one of the regions.
Because the diagnosisof DLBis frequentlya complicated task,
given the overlaps withPD and AD, this may lead to misdiagnosis
of the subjects. Since the combination of a clinical and a neuro-
pathological workup is more accurate than just a clinical workup,
we performed the association using only neuropathologically
proven cases. This led to the inclusion of 667 cases and 2624
controls. When performing logistic regression in this subcohort
both APOE and SNCA remained significant, even after multiple
test correction. SCARB2, in turn, shows a suggestive level of as-
sociation (P ¼ 0.0004), consistent with a similar effect size from
a smaller number of samples (Fig. 2). Interestingly, the MAPT
locus, one of the strongest hits in PD, showed no evidence of as-
sociation with DLB, using any of the approaches.
A single marker inFGF20becomes nearly statistically signifi-
cant (P ¼ 6.47 × 10205) when using only pathologically con-
firmed DLB cases. FGF20 is a fibroblast growth factor
expressed throughout the brain and it was recently shown to be
associated with PD (14,20).
Supplementary Material, Table S3 details the top statistically
significant results at the loci and Figures 3–5 show the regional
association at the three most significant hits. None of the remain-
ing regions previously shown to be associated with PD or AD by
GWAS showed sign of strong association with DLB (Supple-
mentary Material, Figures); including LRRK2, which is known
to have both disease-causing mutations as well as risk-conferring
variants for PD.
Although not a GWAS hit, the GBA gene is a known strong
risk factor for PD and the p.N370S variant has been identified
as the most common variant to impart risk for this disease in Cau-
casian populations (21). Our results do not strongly confirm the
association of this variant with DLB (P ¼ 0.005). Though not a
Gaucher’s disease-causing mutation, the p.E326K variant in
GBA has recently been shown to also increase risk for PD and
DLB (22,23). Again, our data do not strongly support the
involvement of the p.E326K variant in DLB (P ¼ 0.08).
DISCUSSION
The main aim of this study was to determine whether genetic loci
associated with PD or AD are involved in DLB. To that end, we
used a large DLB cohort, comprised mostly of neuropathologi-
cally diagnosed samples, and genotyped markers in previously
reported loci.
A study of this size does not have sufficient statistical power to
identify novel associations of small to intermediate effect size.
However, we estimate that we have excellent power to detect
ORs of .10 for rare variants (,0.01 frequency in the general
population) as is the case of APOE in AD, and over 80%
power to detect variants with OR of 3 and a frequency in the
general population .0.02. Despite these facts, this is the
largest ever association study reported in DLB and therefore it
is the most powerful study published so far.
Three loci were unequivocally associated with DLB in this
cohort: the APOE, SNCA and SCARB2 regions.
The association atAPOE is not surprising, as previous studies
had shown this association (24), which is driven by the epsilon4
allele. As the strongest genetic risk factor for AD, a disease char-
acterized by beta-amyloid deposition and not LB formation, it is
interesting that the sameAPOE risk factor involved in AD is also
the strongest genetic risk factor for DLB. Since DLB is not only
characterized by LBs but also cerebral b-amyloidosis (25), it is
likely that the association of DLB with the epsilon4 allele of
Figure1.Genomic overview of the association at 54 genomic regions in a cohort of 788 DLB cases and 2624 controls. These loci correspond to 500 kb flanking regions
of each top association hit from the latest PD and AD GWAS (32 regions from PD and 22 from AD GWAS). The dotted horizontal red line represents our study-wise
Bonferroni correction threshold of 3.7 × 1025.
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APOE is driven by the Ab pathology-promoting effect of this
particular variant. However, Ab-independent mechanisms
cannot be excluded. While this result could be viewed as a
product of the inclusion of AD cases misdiagnosed as DLB in
our cohort, a few factors argue against that hypothesis. Firstly,
the association remains highly significant when we restrict the
Figure 3.Regional association plot of theAPOE genomic locus (the top hit from GWAS in AD) in a cohort of 788 DLB cases and 2624 controls. Coloring is based on
linkage disequilibrium (LD) with the most associated SNP.
Figure 2.Genomic overview of the association using only neuropathologically confirmed DLB cases at the previously reported association hits for PD and AD. These
loci correspond to 500 kb flanking regions of each top association hit from the latest PD and AD GWAS (32 regions from PD and 22 from AD GWAS). The dotted
horizontal red line represents our study-wise Bonferroni correction threshold of 3.7 × 1025.
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analysis to neuropathologically diagnosed DLB cases; and
second, if a contamination with AD cases were to have occurred,
we would expect to see associations with the other reported
GWAS hits in AD.
An association at theSNCA locus is also not entirely surprising
given that the product of that gene, the protein alpha-synuclein, is
the major protein component of LBs. It is, however, surprising
that the association at this locus appears to be distinct from the
Figure 4.Regional association plot at the SNCA locus (the top hit from GWAS in PD) in a cohort of 788 DLB cases and 2624 controls. Interestingly, the top hit at this
locus for PD is not significant in our DLB study (in purple) and the association seems to be 5′ of the gene. Coloring represents LD with the top reported hit for PD.
Figure 5.Regional association plot at the SCARB2 locus (one of the top hits from GWAS in PD) in a cohort of 788 DLB cases and 2624 controls. The top hit in DLB is
not in high LD with the reported hit for PD (in purple). Coloring represents LD with the top reported hit for PD.
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one reported in PD. In that disease, SNCA is the strongest
common genetic risk factor closely followed by the MAPT
locus. However, when we compare the association region
between PD and DLB, it is clear that the haplotype conferring
risk is different in these two diseases, with PD having an associ-
ation 3′ to gene and DLB appearing to occur 5′ of the gene
(Fig. 6A). Although it is not clear at this stage what are the impli-
cations of this disparity, it is possible that it has an influence on
the distribution of the LBs in the brain tissue, given that these are
generally localized to brainstem in PD and have a more wide-
spread distribution in all DLB cases (26), presumably through
differential expression of the gene. The association is maintained
when only neuropathologically proven DLB cases are included
in the analysis. This shows that this novel association is DLB
specific and not due to misdiagnosis of PD with dementia
cases as DLB.
The third association is also on chromosome 4 and also a
PD-reported locus. The SCARB2 gene encodes a lysosomal
protein that is associated with PD, a disease where other lyso-
somal genes have been implicated. However, it is not one of
the strongest genetic risk factors for PD and only after large
meta-analysis of data, does it become statistically significant
(14). It is thus interesting that it is the third strongest risk
factor for DLB in our study. However, and similarly to the
SNCA locus, the association profile of SCARB2 is also different
between PD and DLB, with the top hit in PD not being significant
in DLB (Fig. 6B). Strengthening the hypothesis of the involve-
ment of the lysosome in DLB is the fact that the p.N370S
variant in GBA was shown to be associated with DLB.
However, as genes in the array are not randomly drawn from
the genome, it is impossible to formally assess whether there is
an enrichment of a lysosomal dysfunction signal in these data
and this, therefore, requires further investigation.
It is notable thatGBA shows an association with DLB and that
we have not seen an association between DLB and LRRK2 var-
iants. In agreement with this, others have shown that GBA
encoded PD is more prone to developing dementia than
LRRK2-encoded disease (27,28).
We have previously shown that AD and PD do not share asso-
ciation regions between them (29). The data we present in this
paper offers a possible explanation for this lack of overlap. Diag-
noses of PD and AD are designed to separate these entities. DLB
is the diagnosis made in those who have elements of both path-
ologies, and in agreement with this, they share risk loci with
AD and PD. However, we also show that the associations with
DLB are different from those in PD, in that they implicate differ-
ent regions of the pathogenic loci, presumably relating to differ-
ent gene expression control elements.
We have also tested if there is an overrepresentation of pre-
viously associated variants for PD and AD as associated with
DLB in our cohort. We were able to either directly assay or
use a proxy (r2 . 0.8) for 37 of the 54 previously associated
markers with PD or AD. Of these, 33 showed a P-value
,0.05. Using a binomial test, we calculated that there is a sig-
nificant overrepresentation of significantly associated variants
(P , 2.2 × 10216).
Here, we have performed a large association study in DLB
to assess if loci previously implicated in AD and PD also play
a role in this disease. We identified three genomic regions
that are involved in DLB. We also show that the association
at the APOE locus is similar to the one that occurs in AD, in
accordance with previous studies, and that the SNCA and
SCARB2 associations are different to the ones reported in PD
and possibly PD with dementia. The possible involvement of
SCARB2 and the previously identified results at GBA seem to
implicate the lysosome in the etiology of this prevalent dis-
order. Overall, these results suggest that the etiology of DLB
is influenced by some of the same genetic risk factors for AD
and PD, but that these loci may act in subtly different manners.
Clearly, large studies on this disorder are needed and to assist
these we make our data available (Supplementary Material,
Table S4).
Figure 6.Comparison of the regional association at the SNCA and SCARB2 loci between DLB and PD. Red symbols represent the PD association (restricted to the top
hits per region), while the blue ones represent DLB. P-values were normalized for each region/study to allow for a better comparison of regional association.
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MATERIALS ANDMETHODS
DLB cases were selected based on clinical and/or neuropatho-
logical diagnosis criteria. In both cases, diagnosis was made
according to the most recently published criteria (7). A total of
121 clinically and 667 neuropathologically diagnosed samples,
originating from 12 study centers, were included in the study
(Table 2). A total of 2624 samples from healthy individuals
were included as a control group (M:F ratio ¼ 0.87). All
samples are from European or North American descent.
All samples were genotyped using the NeuroX array (Illu-
mina, Inc.), which is a publicly available custom array designed
specifically for the study of neurological diseases. In addition to
the base content on Illumina’s Exome BeadChip, the NeuroX
contains markers specific for neurological diseases, in the form
of known and unpublished GWAS hits, rare, high effect size
variants as well as rare variants identified through exome-
sequencing studies of neurodegenerative diseases.
After DNA preparation and genotyping according to standard
Illumina Infinium methods, variants were clustered using Illumi-
na’s GenomeStudio. The base content of the array was clustered
according to the published cluster file from the CHARGE con-
sortium (30), while the custom content, comprising 25 000
variants, was manually assessed/clustered whenever GenTrain
scores were,0.9. Markers that were impossible to cluster prop-
erly were excluded. The entire array content was used for QC
methods, which included removing markers with missingness
.10%, a minor allele frequency of ,1%, those deviating
from the Hardy–Weinberg equilibrium (P , 1 × 1024) and
finally also excluding samples with .10% of missing geno-
types. Following these QC steps, the total cohort comprised of
788 cases and 2624 controls genotyped at 79 152 markers.
Since the aim of this study was to verify if DLB shares genetic
risk with PD and AD, we extracted all variants within 500 kb of
reported association hits for these two diseases. For AD, we used
the data recently published (11), while for PD, because the work
is currently under submission, we used unpublished data. For
each study, we selected the top hit in each associated genomic
region surpassing genome-wide Bonferroni correction (relevant
to each separate study) and identified a region of interest of 1 Mb
in total. A total of 7275 markers were extracted from the entire
content, with 1325 being independent variants (pairwise r2
,0.5).
To generate covariates for logistic regression models, multidi-
mensional scaling was used to quantify genetic distances
between members of the case–control cohort. Association
testing was performed using the logistic regression function in
PLINK (31) using gender and the first 10 principal components
as covariates to adjust for possible population substructure.
We used a conservative Bonferroni significance threshold of
P ¼ 3.7 × 1025 for all associations tested. This threshold was
based on the total number of independent tests performed at
the previously reported hit regions (0.05/1325).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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